Skip to main content

Apogee Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 10, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 10, 2025

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

Checking your notes…

Page
PART IFINANCIAL INFORMATION1
Item 1.Condensed Consolidated Financial Statements (Unaudited)1
Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 20241
Condensed Consolidated Statement of Operations for the Three and Nine Months Ended September 30, 2025 and 20242
Condensed Consolidated Statement of Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 20243
Condensed Consolidated Statement of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2025 and 20244
Condensed Consolidated Statement of Cash Flows for the Nine Months Ended September 30, 2025 and 20246
Notes to the Unaudited Interim Condensed Consolidated Financial Statements7
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations25
Item 3.Quantitative and Qualitative Disclosures About Market Risk43
Item 4.Controls and Procedures43
PART IIOTHER INFORMATION44
Item 1.Legal Proceedings44
Item 1A.Risk Factors44
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds76
Item 3.Defaults Upon Senior Securities76
Item 4.Mine Safety Disclosures76
Item 5.Other Information76
Item 6.Exhibits77
Signatures78
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.